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Abstract
Activation of the stem cell transcriptional circuitry is an important event in cancer development. Although cancer cells
demonstrate a stem cell-like gene expression signature, the epigenetic regulation of pluripotency-associated genes in
cancers remains poorly understood. In this study, we characterized the epigenetic regulation of the pluripotency-associated
genes NANOG, OCT4, c-MYC, KLF4, and SOX2 in a variety of cancer cell lines and in primary tumor samples, and investigated
the re-activation of pluripotency regulatory circuits in cancer progression. Differential patterns of DNA methylation, histone
modifications, and gene expression of pluripotent genes were demonstrated in different types of cancers, which may reflect
their tissue origins. NANOG promoter hypomethylation and gene upregulation were found in metastatic human liver cancer
cells and human hepatocellular carcinoma (HCC) primary tumor tissues. The upregulation of NANOG, together with p53
depletion, was significantly associated with clinical late stage of HCC. A pro-metastatic role of NANOG in colon cancer cells
was also demonstrated, using a NANOG-overexpressing orthotopic tumor implantation mouse model. Demethylation of
NANOG promoter was observed in CD133+high cancer cells. In accordance, overexpression of NANOG resulted in an increase
in the population of CD133+high cells. In addition, we demonstrated a cross-regulation between OCT4 and NANOG in cancer
cells via reprogramming of promoter methylation. Taken together, epigenetic reprogramming of NANOG can lead to the
acquisition of stem cell-like properties. These results underscore the restoration of pluripotency circuits in cancer cells as a
potential mechanism for cancer progression.
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Introduction
Epigenetic changes are considered as potent surrogates to
mutations in the deregulation of growth-promoting genes and
tumor-suppressor genes [1,2]. It has been proposed that the
process of carcinogenesis involves epigenetic alterations in stem/
progenitor cells before gatekeeper gene mutations occur [1,3,4].
This process can presumably affect both the genetic and epigenetic
plasticity of a cell and allow acquisition of ‘‘stemness’’ features,
such as invasion, metastasis and drug resistance, during cancer
progression [1,2]. Moreover, genomic instability caused by global
DNA hypomethylation was found to be one of the earliest changes
in the development of human cancers [2,5].
While overexpression of OCT4, SOX2, KLF4 and c-MYC genes
induce pluripotency in somatic cells leading to the generation of
embryonic stem cell (ESC)-like induced pluripotent stem cells
(iPSCs) [6–8], it is interesting to note that the ESC-like
transcriptional program is often activated in diverse human
epithelial cancers [9,10]. Such an ESC-like gene module was also
associated with disease progression, e.g. metastasis, and early
mortality of breast cancer [9] and bladder cancer [11]. It,
therefore, suggests a common molecular pathway involved in both
iPSC derivation and cancer stem cell (CSC) initiation [12].
Moreover, recent studies have demonstrated that iPSCs retain
epigenetic memory, such as DNA methylation signature, from
their tissue origins [13,14], indicating the importance of epigenetic
regulation in cell fate reprogramming and tumorigenesis [15,16].
Although stem cell-like gene network has been demonstrated in
cancers [11], the association of epigenetic reprogramming and
CSC properties remains poorly understood. Here, we investigated
the epigenetic regulation of pluripotency-associated genes NANOG,
OCT4, c-MYC, KLF4, and SOX2, and their correlation with gene
expression in cancer cell lines and primary tumor samples. We
further examined their potential roles in the process of metastasis
and in the initiation of CSCs during tumor progression.
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Figure 1. Differential methylation of pluripotency-associated genes NANOG, OCT4, and c-MYC in cancer cells. (A) Schematic diagram of
gene regulatory regions of NANOG, OCT4, and c-MYC that were examined by bisulfite sequencing (BiS) (red bars) and ChIP (green bars) experiments.
(i) The NANOG proximal promoter region covers 10 CpG sites from 21449 to 2952. (ii) The OCT4 promoter region is covered by 8 primer pairs for 50
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Materials and Methods
Samples
Paired non-tumor and tumor tissue specimens of hepatocellular
carcinoma (HCC) were collected from fifteen HCC patients
diagnosed with stage I-IV pathologic tumor-node-metastasis
(TNM) disease [17]. Normal liver specimens were obtained from
cadaveric liver donors. All the samples were provided by the
Tissue Bank of Divisions of Hepatobiliary and Pancreatic Surgery
and Liver Transplantation at Department of Surgery, Queen
Mary Hospital. Collection and storage of clinical specimens for the
Tissue Bank has been approved by the Institutional Review Board
of the University of Hong Kong/Hospital Authority of Hong
Kong. Normal hepatocyte and HCC cell lines included MIHA
and L02 (normal hepatocytes); PLC (primary HCC); and
MHCC97L (97L) and MHCC97H (97H), were derived from
metastatic HCC [18]. Other non-HCC cancer cell lines included
HeLa (cervix adenocarcinoma); MCF7 (breast adenocarcinoma);
AGS (gastric adenocarcinoma); HCT116 (colorectal carcinoma);
and K-562 (chronic myelogenous leukemia). The PLC, HeLa,
MCF7, AGS, and HCT116 lines were purchased from the
American Type Culture Collection (ATCC). L02 was obtained
from the China Center for Type Culture Collection.
Genomic DNA isolation
Total genomic DNA was isolated from peripheral blood
mononuclear cells (PBMC), cell lines, and non-tumor and tumor
liver specimens from HCC patients, using the QIAamp DNA mini
kit (Qiagen).
Bisulfite sequencing analysis
Genomic DNA was processed for bisulfite conversion of
unmethylated cytosines using the EpiTect Bisulfite kit (Qiagen).
The bisulfite-modified DNA was used for PCR, with primers that
recognize the converted DNA sequences (Figure 1A; Figure S1 in
File S1; Table S1). PCR products were cloned into pGEM T-Easy
vector (Promega Bioscience). Ten clones were randomly picked
and sequenced. DNA sequences were analyzed with the BIO
Analyzer software (http://biq-analyzer.bioinf.mpi-sb.mpg.de) for
CpG reading. Percentage of methylation refers to the number of
methylated CpGs over the total number of CpGs in the region
analyzed.
Chromatin immunoprecipitation (ChIP)
The ChIP procedure was described in Current Protocols [19].
Briefly, ten to twenty million (1–26107) L02, HCT116 and 97L
cells were collected and fixed with 37% formaldehyde. The
sonicated cell lysates were subjected to immunoprecipitation with
5 mg of H3K4me3 or H3K27me3 antibodies (Abcam), and normal
IgG (inputs as control), respectively, in the presence of protein G-
Sepharose beads (GE Healthcare) at 4uC overnight. Beads were
washed sequentially with FA lysis buffer, ChIP wash buffer, and
TE buffer. Bound materials were eluted with ChIP elution buffer.
Enrichment of histone modification was quantified by real time
PCR, using SYBR Green (Applied Biosystems), with relevant
ChIP primers (Figure 1A; Figure S1 in File S1; Table S1). Data
are presented as fold enrichment, using a ChIP-qPCR analysis
calculation formula (www.sabiosciences.com); inputs and mock IP
were used for normalization.
Reverse transcription and quantitative real time PCR
(qRT-PCR)
Total RNA was isolated using the RNeasy Mini kit (Qiagen)
and treated with DNase I, followed by reverse transcription with
the Transcriptor First Strand cDNA Synthesis Kit (Roche). qRT-
PCR analysis was performed using the pre-designed TaqMan
probes for NANOG (Hs02387400_g1), POU5F1 (Hs00999634_gH),
MYC (Hs00153408_m1), and 18S rRNA (4333760-0807027),
which were selected from TaqMan Gene Expression Assays
(Applied Biosystems). SYBR Green reagents (Applied Biosystems
or TaKaRa Biotechnology) were used for detection of OCT4,
MYC, KLF4, p53 and b-ACTIN gene expression (primer informa-
tion in Table S2). Gene expression was calculated as CT and
normalized to the level of 18S or b-ACTIN.
Lentivirus transduction
Human NANOG (NM_024865) and OCT4 (NM_002701) genes
from human embryonic stem cell line were cloned into pWPI
vector and were transfected with pCMV-dR8.91 and pMD2.G
plasmids into the 293T packaging cell line. Viral supernatants
were harvested 48 hours after transfection and precipitated using
PEG-it Virus Precipitation Solution (System Biosciences).
HCT116 p532/2 cells were infected with lentivirus expressing
CpG sites from22973 to +320. (iii) The c-MYC gene region is covered by BiS primers for CpG islands before TSS1 and TSS2, and CpG sites within Exon
2 and 3; and ChIP primer for Exon 3. (B) Bisulfite sequencing analysis of the NANOG promoter in cancer cell lines. DNA methylation frequency is
presented as percentages in: normal liver (L02) and cancer liver (PLC, 97L, and 97H) cells (blue); normal PBMC and leukemic K-562 cells (orange); and
in HeLa, MCF7, HCT116, and AGS cancer cells (green). (C) Clonal NANOG promoter methylation patterns in 97L, HeLa and K-562 cells. Open circles
represent unmethylated CpGs; closed circles represent methylated CpGs. (D) Methylation frequency of the OCT4 proximal promoter (2530 to +7) in:
normal and cancer liver cells (blue); and in HeLa and HCT116 cells (green). (E) DNA methylation frequency of upstream and downstream regions of
OCT4 in normal and cancer liver cells. ‘‘Overall’’ covers 50 CpG sites from 22973 to +320; ‘‘59 TSS’’ covers 10 CpG sites from 2530 to +7; and ‘‘39 TSS’’
covers 12 CpG sites from +61 to +320. (F) Methylation frequency of exon 3 of c-MYC (10 CpG sites) in: normal and cancer liver cells (blue); PBMC and
leukemic K-562 cells (orange); and in HeLa, MCF7, HCT116, and AGS cancer cells (green).
doi:10.1371/journal.pone.0072435.g001
Table 1. Correlation between metastatic clinicopathological
parameters and mRNA expression of NANOG and p53 in HCC.
Parameters Category
NANOG
mRNA p p53 mRNA p
low high high low
Tumor TNM
stage
I and II 5 1 0.011* 4 2 0.047*
III and IV 1 8 1 8
Venous
infiltration
Absent 5 3 0.084 5 3 0.019*
Present 1 6 0 7
Tumor nodules 1 nodule 5 5 0.294 5 5 0.084
$2 nodules 1 4 0 5
Tumor size #5cm 5 5 0.294 4 6 0.434
.5cm 1 5 1 4
*p,0.05 was considered as statistically significant.
doi:10.1371/journal.pone.0072435.t001
Epigenetic Regulation Pluripotent Genes in Cancers
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e72435
Figure 2. A correlation between pluripotency-associated gene expression and histone modification patterns in normal and cancer
cells. Expression levels of (A) NANOG, (B) OCT4, (C) c-MYC, and (D) KLF4 genes were determined in L02, PLC, 97L, and HCT116 cells by qRT-PCR
analysis, normalized with the reference gene 18S. The gene expression was normalized to L02 sample, which was defined as 1. Data are the mean 6
SD obtained from 2 to 3 experiments with duplicates. Enrichment of histone modification H3K4me3 and H3K27me3 at the promoter regions of
pluripotency-associated genes (E) NANOG, (F) OCT4, (G) c-MYC, and (H) KLF4 were measured in L02, 97L, and HCT116 by ChIP analysis. Data are
represented as fold enrichment and normalized with input and mock IgG controls. The fold enrichment was relative to L02 sample, which was
defined as 1. Data are represented with mean value obtained from two ChIP experiments with error bars of standard derivation.
doi:10.1371/journal.pone.0072435.g002
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either OCT4 or NANOG in the presence of 8 mg/ml protamine
sulfate. Cell sorting was carried out using FACSAria (BD
Biosciences) for isolation of transduced HCT116 p532/2 cells.
Figure 3. Deregulation of NANOG in HCC primary tumor tissue. (A) H&E staining of human normal liver (left), and HCC non-tumor (middle)
and tumor tissue (right). (B) Methylation status of the NANOG promoter (21449 to 2952) in fifteen paired HCC non-tumor and tumor tissues. DNA
methylation frequency was classified into 50–69% (black), 30–49% (grey), and 19–29% (white) in HCC tumor and adjacent non-tumor tissues. (C)
NANOG promoter methylation pattern is represented with HCC case-297 tumor and adjacent non-tumor tissue. (D) Statistical comparison of NANOG
promoter methylation in normal liver (n = 3), HCC adjacent non-tumor (n = 15) and tumor (n = 15) tissues; data are the mean 6 SD. (E) Statistical
comparison of NANOG gene expression in paired HCC non-tumor and tumor tissue (n = 15). Each tumor tissue was normalized with its corresponding
non-tumor tissue.
doi:10.1371/journal.pone.0072435.g003
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Figure 4. NANOG promotes tumor metastasis in a mouse model and enhances cancer cell CD133+high population. (A) HCT116 p532/2
or NANOG-expressing HCT116 p532/2 cells (16106) were injected into nude mice subcutaneously. Xenograft tumor tissue that formed was excised
and dissected into 1–2 mm3 cubes that were then implanted into the cecums of other nude mice. Tumor formation in the cecum was observed after
implantation. Arrows point to cecum and the newly formed tumor in the cecum. (B) Colon to lung tumor metastasis was examined after four weeks
implantation by H&E staining of lung tissue sections. Compared to clear lung tissue (left), a small tumor lesion was observed in the lung (middle) from
the HCT116 p532/2 implantation group; whereas large and multiple colon tumor lesions were found in the NANOG-HCT116 p532/2 implantation
group (right). (C) Statistical comparison of lung metastasis frequency in the orthotopic cecum implantation model derived from HCT116 p532/2
Epigenetic Regulation Pluripotent Genes in Cancers
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In vivo metastasis assay by orthotopic colon tumor
implantation
Four to six weeks old BALB/cAnN-nu (Nude) mice were
obtained and maintained at Laboratory Animal Unit of The
University of Hong Kong. All mouse experiments were approved
by The Committee on the Use of Live Animals of The University
of Hong Kong. Lentivirus infected HCT116 p532/2 cells were
injected subcutaneously into nude mice to generate primary
tumors. The primary tumors were dissected into 1–2 mm3 cubes
and then implanted into the cecum of other nude mice [20]. Colon
to lung tumor metastasis was examined after 4 weeks of cecum
implantation. The whole lungs from nude mice were sectioned
and stained with H&E. The colon tumor lesions in the lungs were
examined by microscopy.
Flow cytometry and cell sorting
CD133-PE (Miltenyi Biotec) labeled HCT116 cells were
analyzed using FACSCalibur (BD Biosciences). CD133+low,
CD133+high, and CD1332 cells were subjected to cell sorting by
FACSAria (BD Biosciences).
Statistical analysis
Data were presented as the mean 6 SD and the Student’s t test
was performed using SPSS software. P,0.05 was regarded as
statistically significant.
(n = 8) and NANOG-HCT116 p532/2 (n = 11). (D) Flow cytometry analysis of CD133 expression in HCT116 cells demonstrated three populations of
cells; namely CD1332, CD133+low, and CD133+high. Less than 1% of cells were regarded as CD133+high. (E) NANOG promoter methylation patterns in
CD1332, CD133+low, and CD133+high HCT116 cells. CD133+high cells demonstrated a significant reduction of NANOG promoter methylation. (F)
NANOG expression in CD1332, CD133+low, and CD133+ high HCT116 cells. CD133+high cells demonstrated a significantly increased NANOG expression.
The NANOG expression in CD1332 was defined as 1, and fold increase in CD133+low and CD133+ high (versus to CD1332) was calculated as DDCT.
Data are the mean 6 SD from three experiments with duplicates. (G) HCT116 cells were infected with NANOG-GFP lentivirus and analyzed for CD133
populations by flow cytometry. The percentages of CD133 populations were compared between HCT116 cells with either endogenous level or
overexpression level of NANOG. The CD133+high population (R5) was increased in cells with overexpression of NANOG.
doi:10.1371/journal.pone.0072435.g004
Figure 5. Cross-regulation of NANOG and OCT4 in HCT116 cancer cells. (A) HCT116 p53+/+ and p532/2 cells were infected with OCT4-GFP-
lentivirus. Strong induction of endogenous NANOG expression was found in OCT4-expressing HCT116 p532/2 cells. The gene expression in HCT116
cells without infection was defined as 1, and fold increase in HCT116 cells with infection was calculated by DCT. Data are the mean 6 SD from three
experiments with duplicates. Paired Student t test was used for statistical analysis. (B) NANOG promoter methylation patterns in HCT116 p53–/– cells
with or without OCT4 overexpression. (C) HCT116 cells were infected with NANOG-GFP-lentivirus. Significant induction of endogenous OCT4
expression was found in both NANOG-expressing HCT116 p53+/+ and p532/2 cells. The gene expression calculation was the same as described in
(A). Paired Student t test was used for statistical analysis.
doi:10.1371/journal.pone.0072435.g005
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Results
Differential DNA methylation of pluripotency-associated
genes in cancer cells
Previous studies have demonstrated the activation of down-
stream targets of NANOG, OCT4, SOX2 and MYC genes in
aggressively growing human cancers [11]. We therefore investi-
gated the CpG methylation pattern of NANOG (also known as
NANOG1), OCT4, SOX2, KLF4 and c-MYC in human cancer cell
lines by bisulfite sequencing approach (Figure 1A; Figure S1 in
File S1). Compared to normal liver cells L02, which displayed a
modest methylation level (39%), DNA hypomethylation of NANOG
(Figure 1A–i) was observed in three liver cancer cell lines, namely
PLC, 97L and 97H (18%, 8% and 14%, respectively), among
which the metastatic liver cell line 97L showed nearly absence of
DNA methylation (Figure 1B and 1C). While in leukemic K-562
cells, NANOG methylation (39%) showed a 2-fold decrease when
compared to normal peripheral blood mononuclear cells (PBMCs)
(81%; Figure 1B and 1C). Cancer cells from other tissue origins
displayed differential NANOG promoter methylation; for example,
hypomethylation was observed in HeLa (25%), whereas hyper-
methylation was shown in MCF7, HCT116 and AGS (71%, 92%
and 91%, respectively) (Figure 1B and 1C).
We next examined the OCT4 promoter methylation pattern in
cancer cells. The proximal promoter region (2503 to +7;
Figure 1A–ii) of OCT4 was found hypermethylated in L02
(92%), MIHA (90%), HeLa (90%) and HCT116 (87%) cells,
which is in contrast to the reduced levels observed in PLC and
97L cells (70% and 41%, respectively; Figure 1D). We extended
the methylation analysis to a total of 50 CpGs that cover both the
distal promoter and downstream region of the transcription start
site (TSS, 22973 to +320; Figure 1A–ii). The reduced
methylation pattern was conserved at the analyzed OCT4 gene
region in PLC and 97L cells (Figure 1E). For the c-MYC gene,
although the CpGs located upstream of TSS1 and TSS2 and
within exon 2 remained unmethylated in both normal and cancer
cells (Figure 1A–iii; Figure S2 in File S1), the methylation level of
exon 3 was dramatically reduced and became hypomethylated in
two liver cancer cell lines, PLC (34%) and 97L (6%), when
compared to the moderate to high level of methylation (51% to
82%) in normal liver cells (Figure 1F). In contrast, cancer cells
from other tissue origins, with the exception of HeLa, displayed
hypermethylation status of c-MYC exon 3 (ranging from 72% to
99%; Figure 1F). On the other hand, CpG islands at the
promoter regions of KLF4 and SOX2 genes remained unmethy-
lated in all the examined cell lines (Figures S1, S3, S4 in File S1).
Taken together, differential methylation pattern of pluripotency-
associated genes was observed in human cancer cell lines from
different tissue origins.
Epigenetic regulations of pluripotent gene expression
We next focused on the pluripotent gene expression in two
cancer cell lines, 97L and HCT116, which showed opposite
patterns of DNA methylation. qRT-PCR analysis demonstrated
higher expression of NANOG, OCT4 and c-MYC genes in 97L cells
but not in HCT116 cells, when compared to control L02 and PLC
cells (Figure 2A–C; Figure S5A–C in File S1), suggesting the
expression of these genes is negatively regulated by DNA
methylation. For KLF4, increased gene expression was observed
in both 97L and HCT116 cells (Figure 2D; Figure S5D in File S1)
despite the fact that the CpG island methylation pattern was
indistinguishable between normal and cancer cells (Figure S3 in
File S1).
Epigenetic modifications on histone proteins also showed strong
association with gene expression. We, therefore, determined the
presence of two kinds of histone modifications, the active/
permissive tri-methyl-H3K4 (H3K4me3) and the repressive tri-
methyl-H3K27 (H3K27me3), in 97L and HCT116 cancer cells.
ChIP analysis demonstrated a significant enrichment of active
H3K4me3 mark at the promoter regions of NANOG and OCT4
and the exon 3 region of c-MYC in 97L cells, when compared to
L02 and HCT116 cells (Figure 2E–G, left panels). This is in
contrast to the low level of repressive H3K27me3 mark observed
in these cells (Figure 2E–G, right panels). These results suggest that
both histone modifications and DNA methylation function
synergistically in regulating NANOG, OCT4 and c-MYC gene
expression. On the other hand, H3K4me3 was found highly
enriched at the KLF4 promoter of 97L cells, whereas HCT116
cells demonstrated a moderate level of H3K4me3 but with
relatively lower level of repressive H3K27me3 (Figure 2H, right
panel). This may account for the high level of KLF4 gene
expression in both cell lines (Figure 2D), which is independent of
DNA methylation.
NANOG promoter hypomethylation in human HCC
tumor tissue
Given that the differential NANOG methylation pattern in
cancer cell lines can be a consequence of in vitro culturing rather
than association with their tumorigenicity per se, we, therefore,
investigated NANOG promoter methylation in primary HCC
tumors paired with adjacent non-tumor tissues (n = 15), compared
to normal liver samples (Figure 3A). Strikingly, 73% of non-tumor
cases (11 out of 15) were more than 50% methylated, whereas
53% of tumor cases (8 out of 15) were less than 30% methylated at
the NANOG promoter (Figure 3B and 3C). NANOG promoter
methylation levels were significantly reduced in the paired HCC
tumors compared with adjacent non-tumor tissues (p=0.000),
whereas no significant changes were detected between normal and
non-tumor liver tissues (p=0.301; Figure 3D). In accordance with
the reduced promoter methylation, NANOG expression was found
significantly higher in tumor tissue than in non-tumor tissue
(p=0.021; Figure 3E). It is worth noting that HCC samples at
TNM stage III and IV, which is usually present with vascular
invasion, lymph node and distant metastasis [17], was significantly
associated with high NANOG (p=0.011) and low p53 (p=0.047)
expression (Table 1; Table S3). The low level of p53 was also
associated with vascular infiltration (p=0.019; Table 1). These
results suggest that tumor metastasis requires both the upregula-
tion of NANOG via promoter hypomethylation and the suppression
of p53 in HCC.
NANOG expression promotes tumor metastasis
Following the identification of NANOG upregulation in meta-
static HCC cells and tumor samples, we furthered our study to
examine the in vivo function of NANOG in cancer progression.
However, the strong expression of NANOG in HCC cells makes it
difficult to be knocked down efficiently for in vivo functional studies
(data not shown). We, therefore, selected the HCT116 cell line,
which has low endogenous level of NANOG, for overexpression
study. A stable NANOG expressing HCT116 p532/2 cells
(Figure S6A in File S1) were injected into nude mice for tumor
formation. Surprisingly, a minimum of 16104 cells of either
HCT116 p532/2 or NANOG expressing HCT116 p532/2
(NANOG-HCT116 p532/2) cells was sufficient to form subcu-
taneous tumors (Table S4), indicating that a higher level of
NANOG expression could not further enhance the formation of
primary tumors. However, using an orthotopic tumor implanta-
Epigenetic Regulation Pluripotent Genes in Cancers
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tion mouse model, we observed a significantly higher colon to lung
metastasis by implanting xenograft tumors of NANOG-HCT116
p532/2 cells compared to the parental HCT116 p532/2 cells
(Figure 4A–C). This provides strong in vivo evidence to support the
function of NANOG in promoting cancer cell metastasis.
Demethylation of NANOG in CD133+high population of
HCT116 cells
High expression of CD133 is one of the indications of CSC
population in various types of cancers, including colon cancer
[21,22]. Since the three pluripotent genes NANOG, OCT4, and c-
MYC were hypermethylated in colorectal carcinoma HCT116
cells, we asked whether the same pattern of methylation would be
observed in the rare putative CSC population in HCT116 cells.
We observed over 80% of HCT116 cells were CD133+, but only
1% of cells were regarded as CD133+high (Figure 4D). Important-
ly, NANOG promoter methylation was maintained at high level in
both CD1332 and CD133+low HCT116 cells (89% and 78%,
respectively), while it was dramatically reduced to 42% in
CD133+high cells (Figure 4E). The reduced methylation was also
found in accordance with a significant upregulation of NANOG
expression in CD133+high cells (Figure 4F). In addition, overex-
pression of exogenous NANOG in HCT116 cells resulted in an
increase of CD133+high population (Figure 4G), suggesting that
demethylation of NANOG promoter contributes to the initiation of
CSCs in tumor development.
Pluripotency regulatory circuits in cancer cells
OCT4, SOX2, and NANOG have been demonstrated to form a
transcriptional regulatory loop in ESCs for the maintenance of
pluripotency [23–25]. We asked whether such cross-regulation is
conserved in cancer cells with aberrant epigenetic patterns.
HCT116 cells with different p53 genetic backgrounds were used
because p53 was reported as a barrier to the re-establishment of
pluripotency [26]. Interestingly, overexpression of exogenous
OCT4 significantly increased NANOG mRNA levels in HCT116
p532/2 cells, but not in HCT116 p53+/+ cells (Figure 5A;
Figure S6B in File S1). The induction of NANOG expression was
associated with a decreased promoter methylation in OCT4-
HCT116 p532/2 cells (from 95% to 66%; Figure 5B). Moreover,
overexpression of the exogenous NANOG significantly enhanced
OCT4 mRNA levels in HCT116 cells regardless of their p53 status
(Figure 5C). This suggests that the pluripotency regulatory circuit
is conserved in cancer cells and it is partially restored in cancer
cells via the epigenetic mechanism that reprograms NANOG
promoter methylation.
Discussion
Activation of the molecular targets of pluripotency-associated
genes (NANOG, OCT4, SOX2, and c-MYC) is frequently observed in
poorly differentiated cancers [11,27]. OCT4 and NANOG expres-
sion have also been found associated with CSC properties in
human cancers [28–33]. In this study, we have demonstrated a
stem cell epigenetic signature of the pluripotency-associated genes
in cancer cell lines; in particular an increased expression of
NANOG in metastatic HCC cells and in poorly prognostic human
HCC tumors (Figure 1B, 1C, 2A, 3; Table 1), which presumably is
associated with its promoter hypomethylated status and the
suppression of p53. We also noticed that NANOGP8, encodes a
protein with over 99.5% similarity to the authentic NANOG1
protein, is expressed in a variety of cancer cells, including
HCT116 cells [34,35]. It is possible that NANOGP8 level may
interfere with the detection of NANOG expression in our study
since the TaqMan probe used cannot distinguish between the two
gene sequences. Importantly, our data indicated that the strong
NANOG expression was associated with the initiation of a putative
CSC population (Figure 4D–G) and promoted in vivo tumor
metastasis (Figure 4A–C). Therefore, we hypothesize that
demethylation of NANOG occurs during tumor development and
the corresponding expression of NANOG provides tumor cells with
metastatic CSC properties.
Cancer cells have been proposed to adapt to an epigenetic
signature of ‘‘stemness’’. Different cancer cells display their
unique patterns of DNA methylation, histone modifications, and
pluripotent gene expression that may reflect the different tissue
origins. Interestingly, iPSCs harbour residual DNA methylation
signatures of their somatic tissue origin [13–16]. Although it is yet
to be determined whether the phenomenon of epigenetic memory
associates with cancer development, our data suggest the
possibility that different tissue origins of cancers might hold
different carcinogenic potentials when they are subjected to
epigenetic alterations, of which some are more prone to re-
activate pluripotent genes by acquiring a stem cell epigenetic
signature.
OCT4 and NANOG are the core components of protein
complexes for maintaining pluripotency and activating transcrip-
tional regulatory circuit. Our observation of OCT4/NANOG cross-
induction in HCT116 cells further demonstrates a conservation of
cross-regulatory function between pluripotent factors in cancer
cells (Figure 5). Apparently this re-activation of transcriptional
circuits depends on epigenetic reprogramming of the silent
promoters in cancer cells. It is noted that the suppressive role of
p53 in stem cell pluripotency is supported by iPSC studies
[36,26,37]. In our study, the NANOG promoter was hypermethy-
lated in both HCT116 p53+/+ and p532/2 cells (Figure 4E and
5B), suggesting that depletion of p53 function alone does not affect
the ground state of cancer epigenetic patterns. However, enforced
expression of OCT4 caused a partial demethylation of the NANOG
promoter in p53-null cells, but not in p53-expressing cells
(Figure 5B), suggesting that inactivation of p53 facilitates
epigenetic reprogramming of pluripotency circuits in cancer cells
and aids in conferring them with CSC properties.
In conclusion, our results demonstrate that epigenetic regulation
is important for the expression of pluripotency-associated genes in
cancer cells, particularly NANOG, and contributes to the metastatic
potential of CSCs. We believe that the re-activation of pluripo-
tency circuits by aberrant epigenetic alterations is one of the key
events of CSC initiation.
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File S1 Figure S1, Diagram of KLF4 and SOX2 regula-
tory regions, with location of bisulfite sequencing (BiS)
primers (red lines) and ChIP primers (green line). (A)
The KLF4 promoter covers 49 CpG sites from 2388 to +52. (B)
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promoter region: (A) in normal PBMC; (B) in 97L cells; (C) in
HCT116 cells; and (D) at exon 2 in PBMC, MIHA, PLC, and 97L
cells, respectively. Open circles represent unmethylated CpGs;
closed circles represent methylated CpGs. Figure S3, KLF4
methylation patterns and frequency (%) at the promoter region
before the TSS: (A) in PBMC; (B) in PLC; and (C) in HCT116
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(A) NANOG; (B) OCT4; (C) c-MYC; and (D) KLF4 genes were
determined in L02, PLC, 97L, and HCT116 cells by qRT-PCR
analysis normalized with the reference gene b-ACTIN. Data are
the mean 6 SD obtained from 2 to 3 experiments with duplicates.
Figure S6, Overexpression of exogenous NANOG and
OCT4, facilitated by lentivirus infection. (A) Overexpres-
sion of the exogenous NANOG gene was detected in HCT116
p53+/+ and p532/2 cells which were infected with NANOG-
GFP-lentivirus. (B) Overexpression of the exogenous OCT4 gene
was detected in HCT116 p53+/+ and HCT116 p532/2 cells
which were infected with OCT4-GFP-lentivirus.
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qPCR.
(DOCX)
Table S2 Primers for qPCR.
(DOCX)
Table S3 NANOG methylation and expression, and p53
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